Kentucky Center for Clinical and Translational Science

肯塔基州临床和转化科学中心

基本信息

  • 批准号:
    10459638
  • 负责人:
  • 金额:
    $ 331.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-15 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Contact PD/PI: Kern, Philip A. PROJECT SUMMARY – OVERALL The University of Kentucky (UK) Center for Clinical and Translational Science (CCTS) has created an integrated home for clinical and translational research which promotes scientific progress and discoveries at every phase of the translational continuum. The CCTS has partnered with communities in Central Appalachia to address multiple generations of recalcitrant health inequities related in part to the economic distress of rural communities. The CCTS has fundamentally transformed UK and Central Appalachia through the development of strong academic-community research networks and collaborations within the CTSA consortium. Appalachian health disparities are further magnified by the opioid and substance abuse epidemic, which has greatly impacted eastern Kentucky and West Virginia. The strong UK research portfolio puts the UK CCTS in an optimal position to lead local, regional and national research efforts focused on rural health inequities. The aligned missions of UK, UK HealthCare and the CCTS focus on achieving health equity by engaging in highly innovative, collaborative and dynamic translational research to address rural health needs. The CCTS will continue to educate the translational workforce of the future, engage rural communities in translational and bi-directional team science and work with the national network to advance transdisciplinary research and clinical trials through the following Specific Aims: 1) develop, innovate and transform our research environment to promote impactful science and discovery within our integrated health care system to meet the unique health needs of Central Appalachian residents; 2) lead institutional innovation in the delivery of impactful clinical and translational research that covers the lifespan, fully engages the community and embraces team science; 3) catalyze an efficient, university-wide clinical trials organization which adds value to the CTSA consortium by engaging participants from rural Central Appalachia; and 4) foster and enhance a workforce characterized by diversity and inclusivity across all translational science disciplines and populations. The UK CTSA hub is uniquely positioned in the National CTSA Consortium to foster novel technologies, team science, clinical trial start-up and cutting-edge translational research across the lifespan with a focus on rural communities. We have a particular focus on the Central Appalachian community, a rural area with many of the highest levels of health disparities in the nation. This focus will ultimately elevate the health and quality of life of rural communities throughout the United States. Project Summary/Abstract Page 276 Contact PD/PI: Kern, Philip A.
联系PD/PI: Kern, Philip A。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Philip A Kern其他文献

Philip A Kern的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Philip A Kern', 18)}}的其他基金

Mirabegron and tadalafil effectiveness for treatment of prediabetes
米拉贝隆和他达拉非治疗糖尿病前期的有效性
  • 批准号:
    10363388
  • 财政年份:
    2021
  • 资助金额:
    $ 331.99万
  • 项目类别:
Mirabegron and tadalafil effectiveness for treatment of prediabetes
米拉贝隆和他达拉非治疗糖尿病前期的有效性
  • 批准号:
    10532229
  • 财政年份:
    2021
  • 资助金额:
    $ 331.99万
  • 项目类别:
Mechanisms for activation of beige adipose tissue in humans
人体米色脂肪组织的激活机制
  • 批准号:
    10531210
  • 财政年份:
    2020
  • 资助金额:
    $ 331.99万
  • 项目类别:
Mechanisms for Activation of Beige Adipose Tissue in Humans; Supplement
人类米色脂肪组织的激活机制;
  • 批准号:
    10630687
  • 财政年份:
    2020
  • 资助金额:
    $ 331.99万
  • 项目类别:
Mechanisms for activation of beige adipose tissue in humans
人体米色脂肪组织的激活机制
  • 批准号:
    10308496
  • 财政年份:
    2020
  • 资助金额:
    $ 331.99万
  • 项目类别:
The activation of brown and beige fat and role in insulin sensitivity
棕色和米色脂肪的激活及其在胰岛素敏感性中的作用
  • 批准号:
    9241565
  • 财政年份:
    2016
  • 资助金额:
    $ 331.99万
  • 项目类别:
Kentucky Center for Clinical and Translational Science
肯塔基州临床和转化科学中心
  • 批准号:
    10185144
  • 财政年份:
    2016
  • 资助金额:
    $ 331.99万
  • 项目类别:
Kentucky Center for Clinical and Translational Science
肯塔基州临床和转化科学中心
  • 批准号:
    10681386
  • 财政年份:
    2016
  • 资助金额:
    $ 331.99万
  • 项目类别:
Kentucky Center for Clinical and Translational Science
肯塔基州临床和转化科学中心
  • 批准号:
    9314011
  • 财政年份:
    2016
  • 资助金额:
    $ 331.99万
  • 项目类别:
Kentucky Center for Clinical and Translational Science
肯塔基州临床和转化科学中心
  • 批准号:
    10733214
  • 财政年份:
    2016
  • 资助金额:
    $ 331.99万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 331.99万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了